Biopharmaceutical News and Research

RSS

New Medicare changes ease cost burden for cancer drugs

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000-until recently.

25 Apr 2025

Insights into Raman spectroscopy as a bioprocess analytical technique

Dr. Nimesh Khadka discusses Raman spectroscopy's role in bioprocess monitoring, highlighting its advantages in molecular specificity and real-time analysis.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 23 Apr 2025

Boost your transfection success with these proven expert tips

Gain expert insights in this interview on achieving transfection success. Explore proven strategies to optimize your approach and enhance results.

From Sartorius 22 Apr 2025

Source Bioscience acquires Cambridge Clinical Laboratories

Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalized healthcare testing services.

10 Apr 2025

New drug compound prevents long COVID symptoms in mice

Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.

8 Apr 2025

New drug strategy targets Staphylococcus aureus toxin to treat pneumonia

Pneumonia caused by the bacterium Staphylococcus aureus is one of the most dangerous infections that can occur in hospital.

2 Apr 2025

Assessing the impact of the particle drift effect on oral drug absorption using flux tools

Discover how particle drift analysis using flux tools improves oral drug absorption in pharmaceutical research.

From Pion Inc 31 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

Study demonstrates successful gene therapy for maple syrup urine disease

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine disease (MSUD) prevented newborn death, normalized growth, restored coordinated expression of the affected genes and stabilized biomarkers in a calf as well as in mice.

28 Feb 2025

Innovative combination of treatments effectively kills acute myeloid leukemia cells

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer.

27 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Inhalable gene therapy tested for cystic fibrosis treatment in the UK and Europe

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

20 Feb 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025

Study examines how diet impacts gene expression in fat tissue

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC.

8 Feb 2025

SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers.

From SAb Biotherapeutics, Inc. 6 Feb 2025

Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents.

6 Feb 2025

BEND lipids revolutionize mRNA delivery and gene-editing

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking system and its counterpart on the station.

28 Jan 2025

Research reveals inaccuracies in common gene therapy measurement technique

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several measurement techniques commonly used in gene therapy.

13 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

World’s largest proteomics study launched by UK Biobank

UK Biobank has today announced the launch of the world's most comprehensive study of the proteins circulating in our bodies, which will transform the study of diseases and their treatments.

9 Jan 2025